Bionano Genomics BNGO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Bionano Genomics (BNGO) Core Market Data and Business Metrics
Latest Closing Price
$3.75Price-Earnings Ratio
-0.01Total Outstanding Shares
2.73 Million SharesDividend
No dividendSIC Description
Laboratory Analytical InstrumentsPrimary Exchange
NASDAQHeadquarters
9540 Towne Centre Drive, San Diego, CA, 92121
Historical Stock Splits
If you bought 600 shares of BNGO before August 7, 2023, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| January 27, 2025 | 1-for-60 (Reverse Split) |
| August 7, 2023 | 1-for-10 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 99,641 Shares | 5.1 | 3/14/2025 | 508,169 Shares |
| 117,602 Shares | 4.31 | 2/28/2025 | 506,722 Shares |
| 230,194 Shares | 2.05 | 2/14/2025 | 471,050 Shares |
| 341,680 Shares | 1.3 | 1/31/2025 | 443,900 Shares |
| 22,600,457 Shares | 1 | 1/15/2025 | 20,490,896 Shares |
| 9,975,120 Shares | 1.77 | 12/31/2024 | 17,653,120 Shares |
Cash Flow Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $57.48 Million |
| Net Cash Flow From Operating Activities, Continuing | $-105.18 Million |
| Net Cash Flow From Financing Activities | $57.48 Million |
| Net Cash Flow From Operating Activities | $-105.18 Million |
| Net Cash Flow | $6.58 Million |
| Net Cash Flow From Investing Activities | $54.27 Million |
Income Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Nonoperating Income/Loss | $-17.79 Million |
| Diluted Average Shares | $97.08 Million |
| Basic Average Shares | $97.08 Million |
| Income/Loss From Continuing Operations Before Tax | $-204.09 Million |
| Costs And Expenses | $196.90 Million |
| Cost Of Revenue | $25.98 Million |
Comprehensive Income
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-203.80 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-203.80 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $307,000 |
| Comprehensive Income/Loss Attributable To Parent | $-203.80 Million |
Balance Sheet
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $37.17 Million |
| Fixed Assets | $24.86 Million |
| Other Non-current Assets | $13.91 Million |
| Equity Attributable To Parent | $80.34 Million |
| Other Current Liabilities | $24.84 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||